Gene · 915
CD3D: CD3 delta subunit of T-cell receptor complex
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. CD3D: CD3 delta subunit of T-cell receptor complex. Genes, record 915. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/915
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P04234 | T-cell surface glycoprotein CD3 delta chain | 171 | 31 | Ensembl, GeneID, HGNC |
Source UniProt
Patents608
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| WO 2026193010 A2 | 2026-09-17 | 21 | P04234 | Espacenet |
| EP 4774292 A1 | 2026-07-15 | 268 | P04234 | Espacenet |
| EP 4758171 A1 | 2026-06-17 | 46 | P04234 | Espacenet |
| EP 4752227 A2 | 2026-06-03 | 17 | P04234 | Espacenet |
| JP 2026090249 A | 2026-06-02 | 24 | P04234 | Espacenet |
| JP 2026516046 A | 2026-05-19 | 14 | P04234 | Espacenet |
| JP 2026516052 A | 2026-05-19 | 14 | P04234 | Espacenet |
| JP 2026063132 A | 2026-04-10 | 319 | P04234 | Espacenet |
| JP 2026511221 A | 2026-04-10 | 5 | P04234 | Espacenet |
| JP 2026054469 A | 2026-03-26 | 33 | P04234 | Espacenet |
1 to 10 of 608
See all 608 patentsDrugs16
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| BLINATUMOMAB | CHEMBL1742992 | T cell surface glycoprotein CD3 cross-linking agent | CROSS-LINKING AGENT | ChEMBL |
| CATUMAXOMAB | CHEMBL2108581 | T cell surface glycoprotein CD3 cross-linking agent | CROSS-LINKING AGENT | ChEMBL |
| ELRANATAMAB | CHEMBL4297809 | T cell surface glycoprotein CD3 binding agent | BINDING AGENT | ChEMBL |
| EPCORITAMAB | CHEMBL4650393 | T cell surface glycoprotein CD3 binding agent | BINDING AGENT | ChEMBL |
| FBT-A05 | CHEMBL2109351 | T cell surface glycoprotein CD3 cross-linking agent | CROSS-LINKING AGENT | ChEMBL |
| FLOTETUZUMAB | CHEMBL3990038 | T cell surface glycoprotein CD3 binding agent | BINDING AGENT | ChEMBL |
| FORALUMAB | CHEMBL1743020 | T cell surface glycoprotein CD3 inhibitor | INHIBITOR | ChEMBL |
| GLOFITAMAB | CHEMBL4298092 | T cell surface glycoprotein CD3 binding agent | BINDING AGENT | ChEMBL |
| IMC-GP100 | CHEMBL2109434 | T cell surface glycoprotein CD3 cross-linking agent | CROSS-LINKING AGENT | ChEMBL |
| MOSUNETUZUMAB | CHEMBL4297788 | T cell surface glycoprotein CD3 binding agent | BINDING AGENT | ChEMBL |
1 to 10 of 16
See all 16 drugsTrials532
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07605416 | TECLISTAMAB | PHASE2 | ClinicalTrials.gov | |
| NCT07598396 | MOSUNETUZUMAB | PHASE2 | ClinicalTrials.gov | |
| NCT07588698 | EPCORITAMAB | PHASE2 | ClinicalTrials.gov | |
| NCT07581704 | TECLISTAMAB | PHASE1 | ClinicalTrials.gov | |
| NCT07573670 | BLINATUMOMAB | PHASE2 | ClinicalTrials.gov | |
| NCT07566364 | MOSUNETUZUMAB | PHASE2 | ClinicalTrials.gov | |
| NCT07564453 | BLINATUMOMAB | PHASE2 | ClinicalTrials.gov | |
| NCT07555470 | MOSUNETUZUMAB | PHASE2 | ClinicalTrials.gov | |
| NCT07548450 | MOSUNETUZUMAB | PHASE2 | ClinicalTrials.gov | |
| NCT07531095 | TARLATAMAB | PHASE1 | ClinicalTrials.gov |
1 to 10 of 532
See all 532 trialsNIH grants2,434
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | CD3D papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 27 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 26 | 2025 |
| P30CA014051 | Cancer Center Support (Core) Grant | 11 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 11 | 2025 |
| U19AI057229 | Understanding Influenza and SARS-CoV-2 vaccine responses, in vivo and in vitro | 9 | 2025 |
| ZIAAI001222 | Characterization of the cellular and molecular bases of inborn errors of immunity | 9 | 2025 |
| P30AG017265 | USC/UCLA Center on Biodemography and Population Health | 8 | 2025 |
| R01AI032539 | Cell Biology of Reovirus Infection | 8 | 2025 |
| P30CA010815 | Consolidated Basic Cancer Research Program | 7 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 7 | 2025 |
1 to 10 of 2,434Source NIH's project files
See all 2,434 nih grantsPapers3,597
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Transcriptomic immune subtyping and connectivity mapping nominate DNA methyltransferase inhibitors for immunedepleted melanoma. | Melanoma Res | 2026 | 42777131 | PubTator, text mining | PubMed |
| Flavokawain B inhibits ER-associated protein dislocation and reduces infectious Zika virus production. | Biochem Biophys Res Commun | 2026 | 42679751 | PubTator, text mining | PubMed |
| Iron Dyshomeostasis and Divergent Antigen Presentation Remodeling in Bronchiectasis: A Dual-Dataset Transcriptomic Analysis. | J Inflamm Res | 2026 | 42670432 | PubTator, text mining | PubMed |
| ICU-acquired infections and mortality in community-acquired pneumonia-induced sepsis: Insights from a transcriptomic analysis. | PLoS One | 2026 | 42247411 | PubTator, text mining | PubMed |
| Clonal lineage tracing of innate immune cells in human cancer. | Cancer Cell | 2026 | 42242233 | PubTator, text mining | PubMed |
| Correlation between DPP-4 Gene Expression and T-Cell Subset Marker Genes in Chronic Liver Disease Patients in Eastern India: An Observational Study. | Indian J Endocrinol Metab | 2026 | 42238559 | PubTator, text mining | PubMed |
| Distinct transcription factors control tissue adaptation and effector function in infant and adult memory T cells. | Nat Immunol | 2026 | 42230957 | PubTator, text mining | PubMed |
| Identification of succinylation-related genes in bladder cancer: integration of single-cell and transcriptomic data. | Front Immunol | 2026 | 42220482 | PubTator, text mining | PubMed |
| Clinical and genetic landscape of SCID in Yunnan, China: identification of two novel RAG2 variants. | Sci Rep | 2026 | 42209588 | PubTator, text mining | PubMed |
| Exploration of CD2 and CD3D as potential immune-related biomarkers for IORT in breast cancer treatment. | Medicine (Baltimore) | 2026 | 42065189 | PubTator, text mining | PubMed |
1 to 10 of 3,597
See all 3,597 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/915
GET https://conductscience.org/api/genes/v1/915/patents?page=2